tumor pathway activations inhibited by dovitinib
Showing 1 - 1 of 1
Tumor Pathway Activations Inhibited by Dovitinib Trial in United States (Dovitinib (TKI258))
Completed
- Tumor Pathway Activations Inhibited by Dovitinib
- Dovitinib (TKI258)
-
Birmingham, Alabama
- +48 more
Jan 30, 2017